Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2006

View Archived Issues

Iroxanadine for the prevention of surgery-induced restenosis

Escitalopram, but not duloxetine, affects sexual function in patients with depression

Serono report on a novel PI3K-gamma inhibitor

GSK licenses tumor-specific antigens from Ludwig Institute for Cancer Research

GSK and Galapagos collaborate in osteoarthritis

Provigil indications amended in U.K.

Vical gains access to NIAID grant funding for avian influenza DNA vaccine

Enrollment completed ahead of schedule in ragweed allergy trial of Tolamba

Bavituximab shows signs of antiviral activity in HCV patients

Greater recurrence-free survival for kidney cancer population receiving Oncophage

KRX-1401 has 43% partial response rate in kidney cancer patients

PF-477736: Chk1-inhibitor potentiates the antitumor activity of gemcitabine in vivo

AZD-6244 enters phase II studies

Nastech submits IND for PYY3-36 nasal spray to treat obesity

CTA-012 shows promise in MS disease model

Renovis eyes topline results of SAINT II trial by year-end

Topline results from insomnia study of EVT-201

Axonyx and TorreyPines Therapeutics to merge

GI-4000 studied in early-stage pancreas cancer patients

University of Kentucky to test novel cancer drug DB-67

sNDA filing for Velcade in relapsed or refractory mantle cell lymphoma

Approvable letter for Trexima for migraine

New treatment options for cancer covered in recent patent literature

Recent Aditech Pharma patent discloses novel therapeutics for psoriasis

Bracco reports new agents for magnetic resonance imaging

Pharmacokinetic, safety and efficacy results reported for proapoptotic Apo2L/TRAIL protein

Antisense XIAP inhibitor shows promise in first clinical trial in cancer patients

Phase II results for combination PARP inhibitor and temozolomide in metastatic malignant melanoma

Glatiramer acetate and TV-5010 suppress ulcerative colitis in preclinical studies

N297A: A new anti-mouse CD3 Fc-modified antibody for chronic inflammatory diseases

New compound isolated from Chinese herb inhibits tumor growth in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...